1141 related articles for article (PubMed ID: 32928094)
21. Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility.
Tarn D; Ashley CE; Xue M; Carnes EC; Zink JI; Brinker CJ
Acc Chem Res; 2013 Mar; 46(3):792-801. PubMed ID: 23387478
[TBL] [Abstract][Full Text] [Related]
22. Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis.
She X; Chen L; Yi Z; Li C; He C; Feng C; Wang T; Shigdar S; Duan W; Kong L
Mini Rev Med Chem; 2018; 18(11):976-989. PubMed ID: 27145854
[TBL] [Abstract][Full Text] [Related]
23. Chitosan-capped mesoporous silica nanoparticles as pH-responsive nanocarriers for controlled drug release.
Hu X; Wang Y; Peng B
Chem Asian J; 2014 Jan; 9(1):319-27. PubMed ID: 24115568
[TBL] [Abstract][Full Text] [Related]
24. Biodegradable nanocarriers based on chitosan-modified mesoporous silica nanoparticles for delivery of methotrexate for application in breast cancer treatment.
Shakeran Z; Keyhanfar M; Varshosaz J; Sutherland DS
Mater Sci Eng C Mater Biol Appl; 2021 Jan; 118():111526. PubMed ID: 33255079
[TBL] [Abstract][Full Text] [Related]
25. A surface-grafted ligand functionalization strategy for coordinate binding of doxorubicin at surface of PEGylated mesoporous silica nanoparticles: Toward pH-responsive drug delivery.
Zhang Q; Zhao H; Li D; Liu L; Du S
Colloids Surf B Biointerfaces; 2017 Jan; 149():138-145. PubMed ID: 27750088
[TBL] [Abstract][Full Text] [Related]
26. Thermo-responsive mesoporous silica/lipid bilayer hybrid nanoparticles for doxorubicin on-demand delivery and reduced premature release.
Zhang Q; Chen X; Shi H; Dong G; Zhou M; Wang T; Xin H
Colloids Surf B Biointerfaces; 2017 Dec; 160():527-534. PubMed ID: 29024917
[TBL] [Abstract][Full Text] [Related]
27. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
[TBL] [Abstract][Full Text] [Related]
28. Nanomachines and Other Caps on Mesoporous Silica Nanoparticles for Drug Delivery.
Chen W; Glackin CA; Horwitz MA; Zink JI
Acc Chem Res; 2019 Jun; 52(6):1531-1542. PubMed ID: 31082188
[TBL] [Abstract][Full Text] [Related]
29. Recent Developments in Mesoporous Silica Nanoparticles for Tumor Theranostic Applications.
Wang X; Zheng M; Raza F; Liu Y; Wei Y; Qiu M; Su J
Curr Pharm Des; 2022; 28(2):151-164. PubMed ID: 34766889
[TBL] [Abstract][Full Text] [Related]
30. Egg-yolk core-shell mesoporous silica nanoparticles for high doxorubicin loading and delivery to prostate cancer cells.
Tiburcius S; Krishnan K; Jose L; Patel V; Ghosh A; Sathish CI; Weidenhofer J; Yang JH; Verrills NM; Karakoti A; Vinu A
Nanoscale; 2022 May; 14(18):6830-6845. PubMed ID: 35441642
[TBL] [Abstract][Full Text] [Related]
31. Mesoporous Silica Nanoparticles-Based Nanoplatforms: Basic Construction, Current State, and Emerging Applications in Anticancer Therapeutics.
Feng Y; Liao Z; Li M; Zhang H; Li T; Qin X; Li S; Wu C; You F; Liao X; Cai L; Yang H; Liu Y
Adv Healthc Mater; 2023 Jun; 12(16):e2201884. PubMed ID: 36529877
[TBL] [Abstract][Full Text] [Related]
32. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery.
Tang F; Li L; Chen D
Adv Mater; 2012 Mar; 24(12):1504-34. PubMed ID: 22378538
[TBL] [Abstract][Full Text] [Related]
33. Effect of pH-responsive alginate/chitosan multilayers coating on delivery efficiency, cellular uptake and biodistribution of mesoporous silica nanoparticles based nanocarriers.
Feng W; Nie W; He C; Zhou X; Chen L; Qiu K; Wang W; Yin Z
ACS Appl Mater Interfaces; 2014 Jun; 6(11):8447-60. PubMed ID: 24745551
[TBL] [Abstract][Full Text] [Related]
34. Mesoporous silica nanoparticles for intracellular controlled drug delivery.
Vivero-Escoto JL; Slowing II; Trewyn BG; Lin VS
Small; 2010 Sep; 6(18):1952-67. PubMed ID: 20690133
[TBL] [Abstract][Full Text] [Related]
35. Concept Design, Development and Preliminary Physical and Chemical Characterization of Tamoxifen-Guided-Mesoporous Silica Nanoparticles.
Day CM; Sweetman MJ; Hickey SM; Song Y; Liu Y; Zhang N; Plush SE; Garg S
Molecules; 2021 Jan; 26(1):. PubMed ID: 33406699
[TBL] [Abstract][Full Text] [Related]
36. In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles.
Chen Y; Chen H; Shi J
Adv Mater; 2013 Jun; 25(23):3144-76. PubMed ID: 23681931
[TBL] [Abstract][Full Text] [Related]
37. Mesoporous Silica Platforms with Potential Applications in Release and Adsorption of Active Agents.
Chircov C; Spoială A; Păun C; Crăciun L; Ficai D; Ficai A; Andronescu E; Turculeƫ ȘC
Molecules; 2020 Aug; 25(17):. PubMed ID: 32825791
[TBL] [Abstract][Full Text] [Related]
38. A systemic review on development of mesoporous nanoparticles as a vehicle for transdermal drug delivery.
Kolimi P; Narala S; Youssef AAA; Nyavanandi D; Dudhipala N
Nanotheranostics; 2023; 7(1):70-89. PubMed ID: 36593800
[TBL] [Abstract][Full Text] [Related]
39. Cancer-targeted and intracellular delivery of Bcl-2-converting peptide with functional macroporous silica nanoparticles for biosafe treatment.
Wu Y; Ge P; Xu W; Li M; Kang Q; Zhang X; Xie J
Mater Sci Eng C Mater Biol Appl; 2020 Mar; 108():110386. PubMed ID: 31923940
[TBL] [Abstract][Full Text] [Related]
40. Mesoporous silica nanoparticles facilitating the dissolution of poorly soluble drugs in orodispersible films.
Ṣen Karaman D; Patrignani G; Rosqvist E; Smått JH; Orłowska A; Mustafa R; Preis M; Rosenholm JM
Eur J Pharm Sci; 2018 Sep; 122():152-159. PubMed ID: 29966736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
